MSTN and pancreatic neoplasm: In a randomized, phase 2 trial (NCT01505530), Golan et al. evaluated LY2495655 (anti-myostatin antibody) plus standard-of-care chemotherapy in stage II-IV pancreatic cancer patients utilizing cachexia status as a stratification variable in 125 individuals [119].